Joining FORCES is the FORCE newsletter with news, views and supportive information for individuals concerned about hereditary breast and ovarian cancer.
by Lisa Rezende, PhD
Dr. Mark Greene (Clinical Genetics Branch of the National Cancer Institute) presented research from the National Ovarian Cancer Prevention and Early Detection Study (GOG-0199).
The GOG-0199 study asked high-risk women (those with BRCA1/2mutations or a very strong family history of breast and/or ovarian cancer) to make a choice: either remove their ovaries and fallopian tubes to reduce cancer risk, or undergo enhanced screening using an investigational strategy with CA-125 known as the ROCA model. ROCA follows CA-125 over time to determine whether rising levels can be used to detect ovarian cancer earlier than the standard use of CA-125, which simply classifies each test as normal or abnormal.
The study found that:
Examining tissue from women who underwent risk-reducing salpingo-oophorectomy showed that:
To hear more, watch on-demand presentations of Dr. Greene and others from “What’s New in HBOC Research” on the FORCE website, including: